Direkt zum Inhalt
Merck

Why dried blood spots are an ideal tool for CYP1A2 phenotyping.

Clinical pharmacokinetics (2014-07-02)
Pieter M M De Kesel, Willy E Lambert, Christophe P Stove
ZUSAMMENFASSUNG

Dried blood spot (DBS) sampling has gained wide interest in bioanalysis during the last decade and has already been successfully applied in pharmacokinetic and phenotyping studies. However, all of the available phenotyping studies used small datasets and did not include a systematic evaluation of DBS-specific parameters. The latter is important since several of these factors still challenge the breakthrough of DBS in routine practice. In this study, caffeine and paraxanthine are determined in capillary DBS, venous DBS, whole blood and plasma for cytochrome P450 (CYP) 1A2 phenotyping. The aim of this study was to explore the usefulness of DBS as a tool for CYP1A2 phenotyping. A CYP1A2 phenotyping study was conducted in 73 healthy volunteers who received a 150 mg oral dose of caffeine. Six hours post-administration, caffeine and paraxanthine concentrations and paraxanthine:caffeine molar concentration ratios, i.e., the actual CYP1A2 phenotyping indices, were determined in capillary DBS (obtained by non-volumetric application, direct from the fingertip), venous DBS, whole blood, and plasma. Furthermore, the impact of DBS-specific parameters, including hematocrit, volume spotted, and punch location, was evaluated. Concentrations of caffeine and paraxanthine in capillary DBS were, respectively, on average 12.7 and 13.8% lower than those in venous DBS and 31.5 and 33.1% lower than those in plasma. While these differences were statistically significant (p < 0.001), no significant difference was observed between the paraxanthine:caffeine molar ratios in the distinct evaluated matrices (p ≥ 0.053). This ratio also alleviated the impact of hematocrit and volume spotted. Using the largest DBS-based phenotyping study to date, we have demonstrated that CYP1A2 phenotyping in capillary DBS is a valid and convenient alternative for the classical plasma-based approach. Additionally, we have provided an objective basis as to why DBS are an ideal tool for CYP1A2 phenotyping.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Ameisensäure, reagent grade, ≥95%
Sigma-Aldrich
Ameisensäure, ACS reagent, ≥96%
Sigma-Aldrich
Ameisensäure, ACS reagent, ≥88%
Sigma-Aldrich
Koffein, anhydrous, 99%, FCC, FG
Supelco
Koffein, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Koffein, powder, ReagentPlus®
USP
Koffein, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Ameisensäure, ≥95%, FCC, FG
USP
Koffein-Schmelzpunkt-Standard, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
1,7-Dimethylxanthin, ~98%, solid
Supelco
Coffein Schmelzpunktstandard, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Koffein, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Koffein, Sigma Reference Standard, vial of 250 mg
Sigma-Aldrich
Ameisensäure -Lösung, BioUltra, 1.0 M in H2O
Supelco
Schmelzpunktstandard 235-237°C, analytical standard
Supelco
Mettler Toledo Calibration Substance ME 18872, Caffeine, traceable to primary standards (LGC)
Sigma-Aldrich
Koffein, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
Koffein, meets USP testing specifications, anhydrous
Sigma-Aldrich
Koffein, BioXtra
Koffein für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Koffein, European Pharmacopoeia (EP) Reference Standard